| Drug General Information |
| Drug ID |
D0A7KI
|
| Former ID |
DIB007980
|
| Drug Name |
Abaperidone
|
| Synonyms |
FI-8602
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Phase 1 |
[1]
|
|---|
| Company |
Ferrer Internacional SA
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C25H25FN2O5
|
| Canonical SMILES |
n1c(c2c(o1)cc(cc2)F)C1CCN(CC1)CCCOc1cc2c(c(=O)c(co2)CO)<br />cc1
|
| CAS Number |
CAS 183849-43-6
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 2A receptor |
Target Info |
Modulator |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channelshsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Small Molecule Therapeutics for Schizophrenia, Sylvain Celanire. Page(30). |
|---|
| REF 2 | 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9. |
|---|
